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Abstract. The  mechanisms  of  action  of  extracorporeal  photochemotherapy  (ECP)  in  cutaneous  T-cell 
lymphoma (CTCL) are poorly understood. Recently, ECP has been shown to induce an increase in regulatory 
T cell (Treg) expression and functional activities in Graft-versus-host-disease (GvHD), whereas no data are 
available  in  CTCL  patients.  The  aim of  this  study  is  to evaluate  whether  ECP is  able  to  modulate  the 
expression  levels  of  the  circulating  CD4+CD25+bright  subset  in  CTCL  patients  and  whether  these 
modifications are related to the disease course. The patient population included 43 CTCL and 15 chronic 
GvHD  patients  treated  by  ECP  at  our  institutions  since  1992.  The  expression  of  the  circulating 
CD4+CD25+bright subset was analysed at baseline and sequentially during treatment by flow-cytometry. 
Fifty healthy donors were used as controls. The baseline circulating CD4+CD25+bright percentage values in 
CTCL (median: 4.3%) were similar to those of healthy donors, whereas GvHD showed significantly lower 
values (median: 1.5%; p<0.001). During treatment, CTCL patients were characterised by an early decrease 
(from 4.3% to 2.4% median after 6 months). The CD4+CD25+bright decrease was associated to the disease 
course, as it occurred in 91.3% of responding but in only 25% of PD patients (p=0.0001). On the other hand, 
a significant increase of CD4+CD25+bright cells was observed in GvHD. ECP induces a reciprocal modulation 
of the circulating CD4+CD25+bright  cells  in  CTCL and GvHD, with a downregulation in CTCL potentially 
associated with the response mechanisms.
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Extracorporeal photochemotherapy (ECP) is a therapeutic procedure in which leukapheresed peripheral 
blood mononuclear cells are exposed to ultraviolet A (UVA) light in the presence of the photosensitizer 
DNA-intercalating  agent  8-methoxypsoralen  (8-MOP)  (1).  It  represents  a  frontline  treatment  for 
erythrodermic cutaneous T-cell lymphoma (CTCL) patients (2), with a 63% mean response rate (range 43%-
100%)  (3-4).  In  recent  years,  ECP  has  been  shown  to  induce  significant  clinical  improvement  also  in 
refractory/resistant graft-versus-host-disease (GvHD) after allogeneic bone marrow transplantation (5) and 
has been successfully used in the prevention of solid organ 344 transplant rejection (6).
In  spite  of  this  increasing clinical  evidence, the mechanisms of  action are still  poorly  understood.  The 
activity of ECP in CTCL patients has been suggested to be dependent on the induction of a vaccine-like 
clonotypic immune-mediated response against T-cellclones (7). An apparently opposite mechanism takes 
place in GvHD, in which the ECP clinical activity is mediated by the down-regulation of the activity of T-cell 
clones  and  autoallogeneic  immune responses  (8).  In  both  CTCL  and GVHD,  however,  the  first  step  is 
represented  by  the  induction  of  lymphocyte  apoptosis,  followed  by  the  phagocytosis  of  apoptotic 
lymphocytes by antigen-presenting cells (APCs) or by DCs (9).
Recently, increasing evidence supports the hypothesis that ECP induces an up-regulation of T lymphocyte 
cell subsets with immunosuppressive roperties (regulatory T cells, Treg) in GvHD patients. Treg cells play a 
central role in immune homeostasis  by regulating the maintenance of self-tolerance and are therefore 
essential for the control of autoimmunity and immune responses o transplanted allografts (10-11). Distinct 
Treg opulations have been identified, among which the most extensively studied is the CD4+CD25+bright 
subset. Circulating CD4+CD25+bright cells represent a small subset in healthy individuals accounting for 2% 
to less than 5% of peripheral blood mononuclear cells. CD4+CD25+bright can be antigen-induced, but also 
naturally occurring cells acting in an antigen non-specific manner through contact-dependent T cell-to-T cell 
interactions. Naturally-occurring CD4+CD25+bright cells are characterised by the constitutive expression of 
specific markers, such as the transcription factor forkhead box P3 (FoxP3) (12), the glucocorticoid-induced 
tumour-necrosis factor receptor-related protein (GITR) and the cytotoxic T lymphocyte-associated antigen 
4  (CTLA-4),  whereas  antigen-induced  are  mainly  identified  by  the  expression  of  immunosuppressive 
cytokines (IL-10) and/or transforming growth factor-beta (TGF-β) (10-11).
Several  in  vitro  and in  vivo  studies  ascertained  the  induction  of  Treg  subsets  and  functions  in  GvHD 
patients. Indeed, the infusion of syngeneic ECPtreated apoptotic cells results in increasing Treg levels in 
murine  models,  through  the  development  of  tolerogenic  DCs  (13-14).  Moreover,  the  transfer  of  ECP-
treated cells reverses experimental  GvHD by increasing donor Treg cells (15). An increase of circulating 
CD4+CD25+bright functional Treg has been recently shown in clinical series of 10 (16) and 14 (17) GvHD 
patients undergoing ECP; a stabilization or even an increase in the CD4+CD25+ Treg cells has been also 
found in small series of ECP-treated solid transplant recipients who did not experience a graft immune 
rejection (18-19).
Data on CD4+ CD25+bright Treg cells in CTCL are limited and controversial. The first issue concerns the 
possibility  that  neoplastic  cells  display a  regulatory  T phenotype.  In  vitro studies by  Berger et al.  (20) 
showed that CTCL cells express a Treg CD25+/CTLA4+FoxP3+ phenotype after interaction with DCs loaded 
with apoptotic T cells. A regulatory T-cell phenotype was also demonstrated in vivo in large transformed T 
cells from 4/5 mycosis fungoides patients (21). Capriotti et al. (22) found using real-time quantitative PCR 
that at least one subset of SS patients (less than 30%) express FoxP3 on leukemic cells, whereas other 
studies (23-25) failed to demonstrate these results showing that CTCL cells from both skin and peripheral 
blood do not express FoxP3. A second issue deals with the expression of Treg subsets within the reactive 
inflammatory compartment. Klemke et al. (23) found a very low percentage of Treg cells in both the skin 
and peripheral blood of the 8 SS patients included in the study. Tiemessen et al. (24) partially confirmed 
these results, failing to demonstrate significant differences in Treg levels between 10 CTCL patients and 
controls, even if CTCL patients showed a lower suppressive activity, which inversely correlated with the 
extent of peripheral blood involvement. More recently, increasing number of FoxP3+ reactive infiltrating 
cells were shown in early or infiltrated mycosis fungoide plaques with a marked reduction in tumours or 
large  cell  lymphoma  transformation  (25).  No  data  are  reported  in  literature  as  to  circulating 
CD4+CD25+bright subsets in CTCL patients undergoing ECP. 
In this paper, the circulating levels of the CD4+CD25+bright cells have been sequentially analysed during 
ECP and related to  the clinical  response  in a  group  of  43 CTCL  and 15 GvHD patients  treated at  our 
institutions since 1992. Our purpose is to evaluate the ECP-induced modulation of the CD4+CD25+bright 
cells in CTCL patients and whether these modifications are related to the disease course.
MATERIALS AND METHODS
Patient population 
Forty-three CTCL (17 females and 26 males; median age: 55, range: 25-85 years) and 15 chronic GvHD (7 
females  and  8  males;  median  age:  48,  range:  24-59  years)  patients  were  treated  with  ECP  at  our 
Department from 1992 until 2008 and were included in this study after informed consent. CTCL patients 
included 28 Sézary syndrome (SS) and 15 Mycosis fungoides (MF), diagnosed according to the standard 
EORTC classification (26).  MF patients were staged according to the recently  ISCL/EORTC revised TNM 
classification (27). The majority of MF patients showed an erythrodermic clinical  picture (T4,  n=8);  the 
remaining  had  patch-  (T2a,  n=3),  plaque-  (T2b,  n=3)  and  nodular-disease  (T3,  n=1).  Lymph  node 
involvement was found in 3 MF patients.
Peripheral  blood  involvement  was  graded  according  to  the  criteria  of  the  International  Society  for 
Cutaneous Lymphoma, as follows: absent (less than 5% circulating Sézary cells, B0); minimal (Sézary cell 
count of less than 1,000 mm-3 or less than 20% atypical T cells on peripheral smears (B1); leukemic (B2) 
(28). The B2 score was defined by at least one of the following criteria: 1) absolute circulating Sézary cell 
count of ≥1,000 mm-3; 2) CD4/CD8 ratio of ≥10 caused by an increase in circulating T-cells; 3) increased 
lymphocyte counts with evidence of a T-cell clone in the peripheral blood by polymerase chain reaction 
(PCR);  4)  circulating  CD4+CD7-  value  of  ≥40%;  5)  aberrant  expression  of  T-cell  markers;  and  6) 
chromosomally abnormal T-cell clone. In addition, CD4+CD26- percentage values were used for diagnosis 
(threshold value: more than 30%) and monitoring of peripheral blood involvement (29). The peripheral 
blood  involvement was scored as B0 in 8, B1 in 4 and B2 in 3 MF patients. All the SS patients showed a B2 
leukemic score. Chronic GvHD patients eligible for ECP were in complete remission of primary disease and 
had GvHD refractory  or  resistant  to  steroids  plus  at  least  two different  lines  of  immuno-suppression. 
Chronic GvHD was defined according to the classic clinical manifestations and date of onset (after day 100 
from transplantation).  One patient  received allogeneic  transplant  for metastatic  kidney cancer;  all  the 
others had haematological malignancies (2 acute lymphoblastic leukaemia,2 acute myeloblastic leukaemia, 
3 non-Hodgkin lymphoma and 8 multiple myeloma). All the GvHD patients carried out ECP together with 
immunosuppressive drugs.
Treatment plan and clinical response evaluation 
Extracorporeal  photochemotherapy  (ECP)  treatment  was  administered  by  trained  nursing  staff  under 
medical supervision, using the UVAR II system from 1992 to 1999 and thereafter the UVAR XTS device 
(Therakos,  Johnson  and  Johnson,  King  of  Prussia,  PA,  USA),  according  to  standard  procedures.  Each 
procedure consisted of 5 to 6 cycles of collection and separation of buffy coat leukocytes (2%-5% of total 
circulating  leukocytes),  followed  by  exposure  of  the  pooled  leukocytes  to  UVA  and  8-MOP,  and  then 
reinfusion to the patient. From 1992 to 1996, the photoactive drug 8-methoxypsoralen (8- MOP) was given 
orally at a dose of 0.6 mg/kg one hour before ECP; since 1997, the liquid form of 8-MOP has been added 
directly to the buffy coat, resulting in reliable and sufficient drug levels in the cell suspension during the 
irradiation period.
CTCL patients underwent ECP on 2 consecutive days once a month (1-4); GvHD patients were treated on 2 
consecutive days every week for the first month, then every 2 weeks for 2-3 months, thereafter monthly (5-
6). The patients were required to have received ECP for at least 2 months for GvHD and for at least 6 
months  for  CTCL.  Response  assessment  in  CTCL  patients  was  based on the  measurement  of  clinically 
apparent disease in the skin, lymph nodes, and peripheral blood, according to the pre-treatment staging, 
and defined according to standard criteria as complete response (CR), partial response (PR), stable disease 
(SD) or progression (PD).
CR was defined as the disappearance of all evidence of clinical disease for at least 4 weeks, PR as a 50% 
tumor regression or  greater  and at  least  a  50% reduction in  the SC counts  (in  the patients  with  pre-
treatment  peripheral  blood involvement),  for a minimum of 4 weeks,  without  the appearance of new 
lesions. A patient was defined as “responder” only if a response was achieved in all the pre-treatment sites 
of disease involvement. The cutaneous response was based on the evaluation of the Severity Weighted 
Assessment  Tool  (SWAT)  score,  obtained  as  the  product  of  the  percentage  total  body  surface  area 
involvement of each lesion type (patch, plaque, and tumor or ulceration), multiplied by a weighting factor 
(1 for patches, 2 for plaques, 3 for tumors/ulcers) (30). Lymph node response was assessed by physical 
examination of palpable nodes and, if necessary, biopsy. The response in the blood was determined by 
comparing both the percentage and absolute number of circulating atypical lymphoid cells as determined 
by morphology and flow cytometry before and after treatment. 
Response criteria for GvHD patients were defined as complete response (CR) in the presence of a complete 
resolution of all  GvHD manifestations, partial response (PR) in the presence of an improvement in skin 
involvement on at least 50% of the body surface area. 
Peripheral blood lymphocyte (PBL) flow cytometry 
Peripheral blood lymphocytes (PBL) were analysed according to their immunofluorescence reactivity, using 
a FACSCalibur cytometer (Becton-Dickinson, S. José, CA, USA). Three- and four-colour immunofluorescence 
analyses were performed simultaneously using FITC-, PE-, PerCP- and APC-conjugated antibodies. At least 
10,000 lymphocytes were collected for each antibody combination. Lymphocyte purity was verified by the 
usual  FSC/SSC  parameters  by  means  of  a  CD45  gating  analysis.  Isotype-matched  negative  controls 
conjugated to each fluorochrome were used to set the location of the cursor for each blood sample. A wide 
panel  of  monoclonal  antibodies  directed against  T-cell  antigens,  as  well  as  activation and proliferation 
markers, was tested routinely, including CD4 (Leu-3, clone SK3), CD26 (clone L272), purchased from BD 
Biosciences,  San  Jose,  CA,  USA,  and  CD25  (clone  CD25-3G10).  As  reported  in  the  literature  (31),  the 
CD4+CD25+ population can be divided in two different levels of expression: cells that expresses a low level 
of CD25 (defined CD4+CD25+low) and cells with a higher level of CD25 (defined CD4+CD25+bright) that 
appear as a tail in respect to the major population, containing both CD4+CD25+low and the CD4+CD25- 
cells, in the presence of a fluorescence CD25 intensity equal or more than 100. Clonal TCR rearrangement 
was identified using a panel of 28 MoAbs directed against the variable regions of the β-chain (Serotec Ltd., 
Oxford, UK; Immunotech Coulter Company, Marseille, France; Endogen, Cambridge, MA, USA; Pharmingen, 
S. Diego, CA, USA). For each patient, samples were collected at baseline (the day before the beginning of 
the first ECP course), after 3 and 6 months of treatment, and thereafter every 6 months. The samples 
collected at baseline and after 3 and 6 months of treatment were available in all patients; thereafter, a 
progressive reduction in the number of samples available was observed due to treatment discontinuation 
for  progression or  other  reason,  ongoing  treatment  or  end of  follow-up period.  All  the samples  were 
collected the day before the beginning of the ECP cycle. A cohort of 50 healthy donors (HD) age- and sex-
matched were used as controls.
Statistical analysis
The results of lymphocyte subsets are given as median, 25th percentile and 75th percentile, minimum and 
maximum values. Non-parametric tests were applied to analyze the differences in sample distribution. The 
Mann-Whitney U  test  was used to  evaluate the differences between two groups  of  patients  at  a  set 
interval. The Wilcoxon signed-rank test for paired samples was applied to evaluate differences in repeated 
measures  at  set  intervals.  The  statistical  analysis  was  applied  only  to  baseline,  3rd  and  6th  month 
determinations in which all the patients had their samples available (43 CTCL and 15 GVHD). Fisher’s exact 
probability test was used for cross-table comparisons.
RESULTS
CD4+CD25+bright baseline values 
No significant difference could be found at baseline in the circulating CD4+CD25+bright percentage values 
between CTCL (median: 4.3%; 25%-75% percentile: 2.1-6.1%) and healthy donors (HD)(median: 3.0%; 2.5-
3.6%). GvHD patients showed significantly lower values (median: 1.5%; 1.2-1.7%) than both CTCL and HD 
(p<0.001) (Fig. 1). No differences were found between MF and SS patients or according to the circulating 
Sézary cell (SC) counts.
The TCR-vβ families were evaluated on the CD4+CD25+bright population in 19 patients in whom a specific 
restriction of the TCR β-chain variable region was detectable by flow-cytometry. CD4+CD25+bright cells did 
not show a monoclonal restriction since only 2.9% to 4.1% of this subset expressed the TCR-vβ which 
characterized the clonal population (Fig. 2A, B).
CD4+CD25+bright kinetics during ECP treatment
An opposite trend was observed between CTCL and GvHD patients during ECP. CTCL patients showed an 
early significant decrease in the median percentage values after 3 months from the beginning of ECP, in 
respect to baseline levels (from 4.3% to 2.5%; p=0.0001). The reduction in the CD4+CD25+bright values was 
maintained after 6 months (median: 2.4%; p=0.0026 in respect to baseline), 12 and 18 months of treatment 
(Fig. 3A). At two years of treatment, median values appeared to slightly increase, even if they were still 
lower in respect to baseline levels. All the determinations performed afterwards did not disclose significant 
modifications: the 4 patients in whom the CD4+CD25+bright values were available after more than 2 years 
of treatment maintained lower than baseline values. No differences in the CD4+CD25+bright trends could 
be  demonstrated  between  MF  and  SS.  A  constant  increase  in  the  median  percentage  values  of  the 
CD4+CD25+bright subpopulation was observed from baseline to the 3rd (median: 2%; p=0.0015) and 6th 
month determination (median:  2.4%; p= 0.0003 in respect to baseline) in GvHD patients (Fig.  3B).  The 
increase  continued  for  all  the  treatment  period;  the  median  percentage  values  after  18  months  of 
treatment were nearly double than the baseline levels (from 1.5% up to 2.6%). 
CD4+CD25+bright modulations and disease course
A clinical response was achieved in 23/43 CTCL patients (53.5%), with 5 CR (11.6%). A SD was obtained in 12 
patients, whereas 8 progressed. Overall, CD4+CD25+bright cells decreased during ECP in 33 CTCL patients, 
with a maximum reduction in respect to baseline levels ranging from 10% to 86.2% (median: 56.6%); on the 
other hand, CD4+CD25+bright cells increased in 10 patients (Fig. 4). The decrease of the CD4+CD25+bright 
levels was significantly  associated with the achievement  of clinical  response:  it  was obtained in 91.3% 
responders (5/5 CR + 16/18 PR) and in 12/20 (60%) non-responders (Fisher test. P= 0.018). The difference 
was more pronounced if we consider only PD patients who showed a decrease in only 2/8 cases (25%) 
(Fisher test  vs responders:  p=0.0001).  Patients  who obtained a  long-standing SD during ECP showed a 
CD4+CD25+bright level behavior similar to that of responders, with 10/12 decreases. As to GvHD, 7 patients 
(46.7%)  achieved  a  clinical  improvement.  All  the  GvHD  patients  underwent  a  significant  increase  in 
CD4+CD25+bright without differences between responders and nonresponders.
DISCUSSION
In  this study spanning over a 15-year period, the expression levels of the circulating CD4+CD25+bright 
subpopulation were sequentially analyzed during ECP treatment in 42 CTCL and 15 GvHD patients. Two 
main findings are shown for the first time: 1)  ECP induces a predominant down-regulation of circulating 
CD4+CD25+bright cell subsets in CTCL patients; 2) the reduction of CD4+CD25+bright cells is potentially 
associated with the disease outcome in CTCL. These results therefore highlight the capability of ECP to 
induce a reciprocal modulation of this subpopulation in CTCL in respect to GvHD, even if such comparison 
needs to  be taken with caution,  given the profound differences in  aetiology,  immunology and clinical 
outcome  which  characterize  the  two  diseases.  CD4+CD25+bright  cells  were  higher  at  baseline  but 
decreased during ECP in CTCL patients, whereas they were lower at baseline but increased during ECP in 
GvHD  patients.  Indeed,  the  reduction  in  CTCL  was  evident  from the 3rd  month,  with a  median  value 
decrease from 4.3% at baseline to 2.4% obtained at the 6-month control. Thereafter, CD4+CD25+bright 
remained roughly unchanged, even if the value distribution of this subset implies that further studies are 
needed to confirm these results. The reduction in the circulating CD4+CD25+bright levels is associated with 
the clinical disease course, as it occurs in 91.3% (21/23) of responding but in only 25% (2/8) PD patients. It 
is interesting to note that all the 5 CR patients developed a marked decrease of CD4+CD25+bright levels. 
Moreover, 10/12 patients with a long standing SD status during ECP behave like responders, showing a 
decrease in the CD4+CD25+bright  levels.  Indeed,  the maintenance  of  a  cutaneous and haematological 
stabilisation with a good quality of life, no infections and tolerable itching in an aggressive CTCL form such 
as SS, is to be considered a sign of ECP clinical activity. In contrast, CD4+CD25+bright levels constantly 
increased in  GvHD during  ECP;  the up-regulation of  CD4+CD25+bright  cells  was  not  associated to  the 
disease  outcome  as  happens  in  CTCL.  The  analysis  of  the  percentage  modifications  during  ECP  from 
baseline levels well illustrates this progressive opposite behaviour which broadens during ECP between 
CTCL and GvHD. Rubegni et al. (17) already reported an increase in the CD4+CD25+ circulating subset in 14 
patients with chronic GvHD after 12 months of ECP treatment. Biagi et al. (16) obtained similar results in 10 
GvHD patients; moreover, these authors showed that CD4+CD25+ cells expressed high levels of Foxp3 and 
CD62L and were  functionally  able  to  exert  inhibitory  activities.  Recent  experimental  evidence strongly 
supports these data, showing that GvHD can be considered an imbalance of effector T cells and that the 
transfer of ECP-treated cells reverses GvHD by increasing Treg and reducing effector T lymphocytes (15). 
The expression and role played by Treg in CTCL patients is far less clearly defined due to the presence of 
few  and  controversial  findings  without  data  in   ECP-treated  patients.  As  a  whole,  SS  seems  to  be 
characterized by a peculiar reduction in Treg expression and functions in both skin and peripheral blood, in 
respect to solid tumours which share a Treg increase correlated with an unfavourable prognosis (11). Our 
findings of similar baseline CD4+CD25+bright levels between CTCL patients and healthy donors, confirm 
previous  data  which  reported  similar  (18)  or  even  lower  (17)  Treg  levels  in  10  and  8  SS  patients, 
respectively, with respect to controls. CD4+CD25+bright cells were not found in our study to belong to the 
clonal population, in agreement with previous studies (23-25). Even if Berger et al. (20) showed that the 
conversion of CTCL cells to Treg cells is induced by the exposure to immature DCs loaded with apoptotic 
CTCL cells, a condition which represents an in vitro model of ECP, the same authors reported a Treg in vivo 
phenotype only in 2/50 CTCL cases. The main limit of our study is that the CD25bright expression, which 
was the first and most extensively used phenotypic marker for CD4+ Treg, does no  exclusively identify this 
T-cell population as it can be found at various degrees also on activated T cells and APC (10-11). Indeed the 
long time span of this study, with patient enrolment beginning in 1992, implies that the analysis of the 
transcription factor forkhead box P3 (FoxP3), the most exclusive intracellular marker for the identification 
of Treg, is available only in a minority of patients. FoxP3 represents a crucial transcription factor for the 
functionality  of  CD4+CD25+bright  cells,  as  it  has  been shown that  the inhibitory  properties  lies  in  the 
FoxP3+ subset (10- 12). Functional in vitro studies should therefore also be carried out to ascertain the 
effective suppressive activity of the CD4+CD25+bright subset in SS patients. A FoxP3 cytoplasmic expression 
was found by flow-cytometry in a percentage of CD4+CD25+bright cells ranging from 36% up to 69% (data 
not shown from 7 SS patients included in this study). These  preliminary results suggest that SS patients are 
characterized by a lower and more variable FoxP3 expression than normal subjects, in whom nearly all the 
CD4+CD25+bright cells show an uniformly positive staining (32), and are in keeping with Klemke et al. (23) 
and Tiemessen et al. (24), who reported a lower FoxP3 expression and suppressive activity of Treg cells in 
CTCL with respect to healthy subjects. A variable FoxP3 pattern by SS patients has also been found by 
Walsh et al. (33) who showed an increased expression in association with HTLV-I infection.
The biological significance of the present data, assuming CD4+CD25+bright cells as a surrogate marker for 
CD4+Treg, is intriguing. The functional down-regulation of circulating Treg subsets in CTCL, if confirmed by 
further phenotypic and functional studies,  could induce a less effective suppression of the anti-tumour 
immune responses and thus contribute to the development  of the immunemediated response against 
pathogenic T-cell clones. The favourable prognostic role played by the Treg down-regulation in ECP-treated 
patients  appears  to  be  in  contrast  with  the  increased  accumulation  of  FoxP3+Treg  cells  in  indolent 
patch/plaque  with  respect  to  nodular  CTCL  lesions  (25)  and  the  more  aggressive  SS  disease  course 
associated with the lack of Treg activity (23). However, the prognostic role played by Treg expression is still 
a matter of controversy also in literature: in fact, recent evidence provides the view that FoxP3 expression 
could be related to a worse prognosis (22). Some more insights into this controversial issue could be given 
by the analysis of the re-circulation of Treg cells between peripheral blood and skin. Indeed, results on 
patients with rheumatoid arthritis demonstrated that the percentage of CD4+CD25+ Treg was significantly 
increased in the synovial  fluid with respect to the peripheral  blood (34),  suggesting therefore that the 
recruitment to the inflammatory sites may be responsible for the Treg reduction in the peripheral blood. It 
could therefore be useful in future studies to evaluate Treg expression and the modifications induced by 
ECP also in cutaneous lesions. In conclusion, the analysis of the circulating CD4+CD25+bright subset may 
represent,  from  a  clinical  point  of  view,  an  additional  tool  in  CTCL  management  during  ECP  for  the 
identification of  responsive patients,  whereas,  from a biological  perspective,  it  offers  a  new intriguing 
scenario for a better understanding of ECP-induced immunemodulation.
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Fig.  1.  Percentage  values  of  the  Pbl  CD4+CD25+bright  subset  as  determined  at  baseline  before  the 
beginning of ECP in CTCL, GvHD and HD. The horizontal bars represent median values. ***: p<0.001.
Fig. 2. A representative dot plot from an SS patient, showing that the large majority of CD4+ circulating cells
are  CD25 negative  or  CD25+low (A,  lower rectangle);  only  a  small  subset  of  CD4+CD25+bright  can be 
identified  in  the  peripheral  blood  (A,  upper  rectangle).  CD4+  cells  were  gated  on  the  basis  of  CD25 
expression. In B, CD25+bright gated cells do not express the TCR-vβ of the clonal population, whereas gated 
CD25negative and CD25+low cells show a specific restriction of the TCR β- chain variable region (Fig. 2C).
Fig. 3. Kinetics of the CD4+CD25+bright percentage values in CTCL (A) and GvHD (B) patients during ECP. 
Data are represented as a a box and whisker plot: the ends of the box are the 25th (lower end) and 75th 
percentile (upper end), the median is marked by an horizontal line inside the box and the whiskers are the 
two lines outside the box that extend to the highest and lowest observations. Numbers above each graphic 
represent number of patients tested at each time interval. **: p<0.01; ***: p<0.001.
Fig. 4. Highest percentage modifications of the CD4+CD25+bright levels during ECP treatment with respect 
to baseline values  in  CTCL patients.  The columns above the x  axis  represent  patients  who showed an 
increase of the CD4+CD25+bright subset during ECP; the columns below the x axis represent patients who 
obtained  a  CD4+CD25+bright  decrease  during  ECP.  The  value  of  each  column  indicates  the  highest 
percentage modification with respect to baseline values obtained at whichever time during ECP. Column 
colour  represents  the  response  obtained  by  ECP:  white=CR;  white  with  horizontal  lines=PR;  grey=SD; 
black=PD.
